Literature DB >> 11172178

Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct.

P Hammel1, A Couvelard, D O'Toole, A Ratouis, A Sauvanet, J F Fléjou, C Degott, J Belghiti, P Bernades, D Valla, P Ruszniewski, P Lévy.   

Abstract

BACKGROUND: Chronic obstruction of the common bile duct may cause hepatic fibrosis and secondary biliary cirrhosis.
METHODS: We studied liver-biopsy specimens from 11 patients with chronic stenosis of the common bile duct due to chronic pancreatitis; all the patients had undergone liver biopsy before or at the time of surgical biliary decompression and underwent a subsequent liver biopsy for various clinical reasons. The patients were followed as part of a prospective study of 501 patients who had been treated for chronic pancreatitis. Two pathologists, who were unaware of the sequence of specimens, graded fibrosis on a scale of 0 (none) to 3 (cirrhosis).
RESULTS: The 11 patients were all men. Chronic pancreatitis was due to alcohol abuse in 10 of the men; 1 had idiopathic disease. The median age at diagnosis was 38 years. The median interval between the first and second liver biopsies was 2.5 years (range, 0.3 to 9.0). The two patients who had restenosis of the biliary anastomosis were excluded from the analysis of fibrosis. In the group of nine patients without restenosis, the second specimen showed significant improvement in fibrosis (P=0.01). The fibrosis improved by two grades in two patients and by one grade in four patients; in three patients, the grade did not change. The pathologists agreed on the grading of specimens from 10 of the 11 patients.
CONCLUSIONS: In patients with chronic pancreatitis and stenosis of the common bile duct, liver fibrosis may regress after biliary drainage.

Entities:  

Mesh:

Year:  2001        PMID: 11172178     DOI: 10.1056/NEJM200102083440604

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  86 in total

1.  Liver T1ρ MRI measurement in healthy human subjects at 3 T: a preliminary study with a two-dimensional fast-field echo sequence.

Authors:  M Deng; F Zhao; J Yuan; A T Ahuja; Y-X J Wang
Journal:  Br J Radiol       Date:  2012-03-14       Impact factor: 3.039

2.  Fibrogenic cell reversion underlies fibrosis regression in liver.

Authors:  Scott Laurence Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

3.  What is the role of endotherapy in chronic pancreatitis?

Authors:  Haritha Avula; Stuart Sherman
Journal:  Therap Adv Gastroenterol       Date:  2010-11       Impact factor: 4.409

4.  Novel insights into a reputably irreversible process: combined mRNA and miRNA profiling of tissue from vesicourethral anastomotic stenosis after radical prostatectomy.

Authors:  T S Worst; K Daskalova; A Steidler; K Berner-Leischner; R Röth; B Niesler; C-A Weis; M C Kriegmair; P Erben; D Pfalzgraf
Journal:  World J Urol       Date:  2017-06-20       Impact factor: 4.226

Review 5.  Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis.

Authors:  Adolf Stiehl; Daniel Rost
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

6.  Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression.

Authors:  Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Eun Hee Choi; Jae Yeon Seok; Jung Min Lee; Young Nyun Park; Chae Yoon Chon; Kwang-Hyub Han
Journal:  Hepatol Int       Date:  2010-08-04       Impact factor: 6.047

Review 7.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

Review 8.  [Therapy of chronic pancreatitis].

Authors:  J Mössner; V Keim
Journal:  Internist (Berl)       Date:  2003-12       Impact factor: 0.743

Review 9.  Role of NADPH oxidases in liver fibrosis.

Authors:  Yong-Han Paik; Jonghwa Kim; Tomonori Aoyama; Samuele De Minicis; Ramon Bataller; David A Brenner
Journal:  Antioxid Redox Signal       Date:  2014-01-24       Impact factor: 8.401

10.  Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo.

Authors:  Chunqiu Hao; Yumei Xie; Meijuan Peng; Li Ma; Yun Zhou; Yan Zhang; Wenzhen Kang; Jiuping Wang; Xuefan Bai; Pingzhong Wang; Zhansheng Jia
Journal:  Clin Exp Med       Date:  2013-03-02       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.